Show simple item record

dc.contributor.authorBrugada, Josepen_US
dc.contributor.authorDelnoy, Peter Paulen_US
dc.contributor.authorBrachmann, Johannesen_US
dc.contributor.authorReynolds, Dwighten_US
dc.contributor.authorPadeletti, Luigien_US
dc.contributor.authorNoelker, Georgen_US
dc.contributor.authorKantipudi, Charanen_US
dc.contributor.authorRubin Lopez, José Manuelen_US
dc.contributor.authorDichtl, Wolfgangen_US
dc.contributor.authorBorri-Brunetto, Albertoen_US
dc.contributor.authorVerhees, Lucen_US
dc.contributor.authorRitter, Philippeen_US
dc.contributor.authorSingh, Jagmeet P.en_US
dc.date.accessioned2017-04-06T03:19:12Z
dc.date.issued2016en_US
dc.identifier.citationBrugada, J., P. P. Delnoy, J. Brachmann, D. Reynolds, L. Padeletti, G. Noelker, C. Kantipudi, et al. 2016. “Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial.” European Heart Journal 38 (10): 730-738. doi:10.1093/eurheartj/ehw526. http://dx.doi.org/10.1093/eurheartj/ehw526.en
dc.identifier.issnen
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:32072049
dc.description.abstractAims Although cardiac resynchronization therapy (CRT) is effective in patients with systolic heart failure (HF) and a wide QRS interval, a substantial proportion of patients remain non-responsive. The SonR contractility sensor embedded in the right atrial lead enables individualized automatic optimization of the atrioventricular (AV) and interventricular (VV) timings. The RESPOND-CRT study investigated the safety and efficacy of the contractility sensor system in HF patients undergoing CRT. Methods and results RESPOND-CRT was a prospective, randomized, double-blinded, multicentre, non-inferiority trial. Patients were randomized (2:1, respectively) to receive weekly, automatic CRT optimization with SonR vs. an Echo-guided optimization of AV and VV timings. The primary efficacy endpoint was the rate of clinical responders (patients alive, without adjudicated HF-related events, with improvement in New York Heart Association class or quality of life), at 12 months. The study randomized 998 patients. Responder rates were 75.0% in the SonR arm and 70.4% in the Echo arm (mean difference, 4.6%; 95% CI, −1.4% to 10.6%; P < 0.001 for non-inferiority margin −10.0%) (Table 2). At an overall mean follow-up of 548 ± 190 days SonR was associated with a 35% risk reduction in HF hospitalization (hazard ratio, 0.65; 95% CI, 0.46–0.92; log-rank P = 0.01). Conclusion: Automatic AV and VV optimization using the contractility sensor was safe and as effective as Echo-guided AV and VV optimization in increasing response to CRT. ClinicalTrials.gov number NCT01534234en
dc.language.isoen_USen
dc.publisherOxford University Pressen
dc.relation.isversionofdoi:10.1093/eurheartj/ehw526en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353752/pdf/en
dash.licenseLAAen_US
dc.subjectSonRen
dc.subjectAV and VV optimizationen
dc.subjectCRT optimizationen
dc.subjectCardiac contractilityen
dc.subjectRESPONDen
dc.subjectHF hospitalizationen
dc.subjectAdaptive CRTen
dc.titleContractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trialen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalEuropean Heart Journalen
dash.depositing.authorSingh, Jagmeet P.en_US
dc.date.available2017-04-06T03:19:12Z
dc.identifier.doi10.1093/eurheartj/ehw526*
dash.authorsorderedfalse
dash.contributor.affiliatedSingh, Jagmeet


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record